S&P 500   4,966.81 (-0.88%)
DOW   37,990.25 (+0.57%)
QQQ   414.07 (-2.21%)
AAPL   165.08 (-1.17%)
MSFT   399.12 (-1.27%)
META   477.67 (-4.81%)
GOOGL   153.59 (-1.55%)
AMZN   173.95 (-2.94%)
TSLA   146.60 (-2.22%)
NVDA   764.87 (-9.67%)
AMD   146.22 (-5.71%)
NIO   3.80 (-5.00%)
BABA   69.02 (+0.20%)
T   16.47 (+0.86%)
F   12.09 (+0.25%)
MU   106.31 (-5.02%)
GE   148.30 (-3.03%)
CGC   8.02 (+2.43%)
DIS   112.11 (-0.28%)
AMC   3.14 (+7.53%)
PFE   25.96 (+2.24%)
PYPL   61.87 (-0.37%)
XOM   119.88 (+1.15%)
S&P 500   4,966.81 (-0.88%)
DOW   37,990.25 (+0.57%)
QQQ   414.07 (-2.21%)
AAPL   165.08 (-1.17%)
MSFT   399.12 (-1.27%)
META   477.67 (-4.81%)
GOOGL   153.59 (-1.55%)
AMZN   173.95 (-2.94%)
TSLA   146.60 (-2.22%)
NVDA   764.87 (-9.67%)
AMD   146.22 (-5.71%)
NIO   3.80 (-5.00%)
BABA   69.02 (+0.20%)
T   16.47 (+0.86%)
F   12.09 (+0.25%)
MU   106.31 (-5.02%)
GE   148.30 (-3.03%)
CGC   8.02 (+2.43%)
DIS   112.11 (-0.28%)
AMC   3.14 (+7.53%)
PFE   25.96 (+2.24%)
PYPL   61.87 (-0.37%)
XOM   119.88 (+1.15%)
S&P 500   4,966.81 (-0.88%)
DOW   37,990.25 (+0.57%)
QQQ   414.07 (-2.21%)
AAPL   165.08 (-1.17%)
MSFT   399.12 (-1.27%)
META   477.67 (-4.81%)
GOOGL   153.59 (-1.55%)
AMZN   173.95 (-2.94%)
TSLA   146.60 (-2.22%)
NVDA   764.87 (-9.67%)
AMD   146.22 (-5.71%)
NIO   3.80 (-5.00%)
BABA   69.02 (+0.20%)
T   16.47 (+0.86%)
F   12.09 (+0.25%)
MU   106.31 (-5.02%)
GE   148.30 (-3.03%)
CGC   8.02 (+2.43%)
DIS   112.11 (-0.28%)
AMC   3.14 (+7.53%)
PFE   25.96 (+2.24%)
PYPL   61.87 (-0.37%)
XOM   119.88 (+1.15%)
S&P 500   4,966.81 (-0.88%)
DOW   37,990.25 (+0.57%)
QQQ   414.07 (-2.21%)
AAPL   165.08 (-1.17%)
MSFT   399.12 (-1.27%)
META   477.67 (-4.81%)
GOOGL   153.59 (-1.55%)
AMZN   173.95 (-2.94%)
TSLA   146.60 (-2.22%)
NVDA   764.87 (-9.67%)
AMD   146.22 (-5.71%)
NIO   3.80 (-5.00%)
BABA   69.02 (+0.20%)
T   16.47 (+0.86%)
F   12.09 (+0.25%)
MU   106.31 (-5.02%)
GE   148.30 (-3.03%)
CGC   8.02 (+2.43%)
DIS   112.11 (-0.28%)
AMC   3.14 (+7.53%)
PFE   25.96 (+2.24%)
PYPL   61.87 (-0.37%)
XOM   119.88 (+1.15%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AxoGen, Inc. stock logo
AXGN
AxoGen
$6.40
-2.3%
$8.68
$3.45
$10.83
$279.62M1.03414,067 shs138,769 shs
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$15.62
-1.5%
$17.50
$8.92
$24.50
$707.59M1.67403,459 shs292,381 shs
Natus Medical Incorporated stock logo
NTUS
Natus Medical
$32.96
$32.96
$20.90
$33.93
$1.14B0.22325,002 shs1,514 shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$83.85
-3.9%
$82.97
$36.42
$99.63
$2.74B1.99689,000 shs746,091 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AxoGen, Inc. stock logo
AXGN
AxoGen
-5.62%-10.76%-14.71%-25.40%-35.15%
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
+4.76%-7.25%-10.09%-7.63%-19.86%
Natus Medical Incorporated stock logo
NTUS
Natus Medical
0.00%0.00%0.00%0.00%0.00%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-0.71%-7.14%+18.56%+6.16%+20.13%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AxoGen, Inc. stock logo
AXGN
AxoGen
1.7058 of 5 stars
3.53.00.00.00.02.50.6
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
1.6924 of 5 stars
3.51.00.00.02.02.50.6
Natus Medical Incorporated stock logo
NTUS
Natus Medical
N/AN/AN/AN/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
0.7645 of 5 stars
2.41.00.00.01.82.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AxoGen, Inc. stock logo
AXGN
AxoGen
3.00
Buy$10.6766.67% Upside
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
3.00
Buy$23.4049.81% Upside
Natus Medical Incorporated stock logo
NTUS
Natus Medical
N/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.86
Moderate Buy$102.0021.65% Upside

Current Analyst Ratings

Latest BLFS, NTUS, AXGN, and TMDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/4/2024
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$22.00
3/28/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$95.00
2/28/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$75.00 ➝ $95.00
2/27/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$87.00 ➝ $105.00
2/27/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$92.00 ➝ $105.00
1/19/2024
AxoGen, Inc. stock logo
AXGN
AxoGen
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$12.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AxoGen, Inc. stock logo
AXGN
AxoGen
$159.01M1.76N/AN/A$2.22 per share2.88
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$143.27M4.94N/AN/A$7.67 per share2.04
Natus Medical Incorporated stock logo
NTUS
Natus Medical
$473.44M2.41$2.02 per share16.34$12.44 per share2.65
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$241.62M11.35$0.14 per share617.26$4.20 per share19.96

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AxoGen, Inc. stock logo
AXGN
AxoGen
-$21.72M-$0.52N/AN/AN/A-13.66%-22.38%-11.24%5/2/2024 (Confirmed)
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$66.43M-$1.52N/AN/AN/A-46.37%-13.36%-10.83%5/8/2024 (Estimated)
Natus Medical Incorporated stock logo
NTUS
Natus Medical
$13.18M$0.3789.0820.99N/A2.65%10.15%7.65%N/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-$25.03M-$0.77N/A204.51N/A-10.36%-2.35%-0.60%4/30/2024 (Confirmed)

Latest BLFS, NTUS, AXGN, and TMDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
AxoGen, Inc. stock logo
AXGN
AxoGen
-$0.10N/A+$0.10N/AN/AN/A  
4/30/2024N/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-$0.05N/A+$0.05N/AN/AN/A  
3/5/2024Q4 2023
AxoGen, Inc. stock logo
AXGN
AxoGen
-$0.20-$0.09+$0.11-$0.09$42.70 million$42.92 million
2/29/2024Q4 2023
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$0.24-$0.22+$0.02-$0.14$32.70 million$32.73 million
2/26/2024Q4 2023
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-$0.10$0.12+$0.22$0.12$68.49 million$81.20 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AxoGen, Inc. stock logo
AXGN
AxoGen
N/AN/AN/AN/AN/A
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
N/AN/AN/AN/AN/A
Natus Medical Incorporated stock logo
NTUS
Natus Medical
N/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AxoGen, Inc. stock logo
AXGN
AxoGen
0.71
2.89
2.14
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
0.06
2.86
1.83
Natus Medical Incorporated stock logo
NTUS
Natus Medical
N/A
2.54
1.90
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
3.69
9.30
8.49

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
80.29%
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
93.24%
Natus Medical Incorporated stock logo
NTUS
Natus Medical
92.35%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%

Insider Ownership

CompanyInsider Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
7.21%
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
2.70%
Natus Medical Incorporated stock logo
NTUS
Natus Medical
1.20%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
6.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AxoGen, Inc. stock logo
AXGN
AxoGen
42643.69 million40.54 millionOptionable
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
40945.30 million44.08 millionOptionable
Natus Medical Incorporated stock logo
NTUS
Natus Medical
1,40034.58 million34.17 millionOptionable
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
58432.71 million30.52 millionOptionable

BLFS, NTUS, AXGN, and TMDX Headlines

SourceHeadline
TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein Sells 4,000 SharesTransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein Sells 4,000 Shares
insidertrades.com - April 19 at 6:50 AM
453,615 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Bought by Mackenzie Financial Corp453,615 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Bought by Mackenzie Financial Corp
marketbeat.com - April 18 at 6:30 AM
TransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Rating of "Moderate Buy" from BrokeragesTransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Rating of "Moderate Buy" from Brokerages
americanbankingnews.com - April 18 at 2:32 AM
TransMedics Group (NASDAQ:TMDX) Stock Price Down 6.1%TransMedics Group (NASDAQ:TMDX) Stock Price Down 6.1%
marketbeat.com - April 17 at 2:16 PM
Validea Detailed Fundamental Analysis - TMDXValidea Detailed Fundamental Analysis - TMDX
nasdaq.com - April 17 at 8:57 AM
TransMedics to Report First Quarter 2024 Financial Results on April 30, 2024TransMedics to Report First Quarter 2024 Financial Results on April 30, 2024
finance.yahoo.com - April 16 at 8:10 PM
TransMedics (TMDX) Flat As Market Sinks: What You Should KnowTransMedics (TMDX) Flat As Market Sinks: What You Should Know
zacks.com - April 15 at 7:21 PM
Theres Been No Shortage Of Growth Recently For TransMedics Groups (NASDAQ:TMDX) Returns On CapitalThere's Been No Shortage Of Growth Recently For TransMedics Group's (NASDAQ:TMDX) Returns On Capital
finance.yahoo.com - April 15 at 2:13 PM
Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) CEO Sells 12,000 Shares of StockInsider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) CEO Sells 12,000 Shares of Stock
insidertrades.com - April 14 at 4:20 AM
TransMedics Group, Inc. (NASDAQ:TMDX) CEO Sells $1,141,080.00 in StockTransMedics Group, Inc. (NASDAQ:TMDX) CEO Sells $1,141,080.00 in Stock
marketbeat.com - April 12 at 6:32 PM
Wall Street Favorites: 3 Long-Term Stocks With Strong Buy Ratings for April 2024Wall Street Favorites: 3 Long-Term Stocks With Strong Buy Ratings for April 2024
investorplace.com - April 12 at 4:30 PM
TransMedics group exec sells over $1.79 million in company stockTransMedics group exec sells over $1.79 million in company stock
investing.com - April 12 at 9:43 AM
3 Must-Own Stocks for Sustained Growth Over the Next 18 Months3 Must-Own Stocks for Sustained Growth Over the Next 18 Months
investorplace.com - April 12 at 6:30 AM
Tamer I. Khayal Sells 15,512 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) StockTamer I. Khayal Sells 15,512 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock
americanbankingnews.com - April 12 at 4:36 AM
The 3 Most Promising MedTech Stocks to Invest In NowThe 3 Most Promising MedTech Stocks to Invest In Now
investorplace.com - April 11 at 2:55 PM
Heart And Lung Transplants Drive Medical Stock Higher As S&P 500 FizzlesHeart And Lung Transplants Drive Medical Stock Higher As S&P 500 Fizzles
finance.yahoo.com - April 11 at 2:12 PM
Organ Transplant Stock Surges Past Buy Point Even As S&P 500 FizzlesOrgan Transplant Stock Surges Past Buy Point Even As S&P 500 Fizzles
investors.com - April 11 at 10:55 AM
TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by Peregrine Capital Management LLCTransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by Peregrine Capital Management LLC
marketbeat.com - April 11 at 7:49 AM
Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells 15,512 Shares of StockInsider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells 15,512 Shares of Stock
insidertrades.com - April 11 at 6:37 AM
TransMedics Group (NASDAQ:TMDX) Trading Up 2%TransMedics Group (NASDAQ:TMDX) Trading Up 2%
marketbeat.com - April 10 at 2:51 PM
Moody Aldrich Partners LLC Buys 24,290 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)Moody Aldrich Partners LLC Buys 24,290 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)
marketbeat.com - April 9 at 1:32 PM
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
prnewswire.com - April 8 at 4:05 PM
Kent Lake Capital LLC Has $4.34 Million Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)Kent Lake Capital LLC Has $4.34 Million Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)
marketbeat.com - April 6 at 7:36 PM
TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells $397,540.92 in StockTransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells $397,540.92 in Stock
insidertrades.com - April 6 at 7:39 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AxoGen logo

AxoGen

NASDAQ:AXGN
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
BioLife Solutions logo

BioLife Solutions

NASDAQ:BLFS
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Natus Medical logo

Natus Medical

NASDAQ:NTUS
Natus Medical Incorporated provides medical device solutions focuses on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and technologies used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. In addition, it offers electroencephalography, long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, and intra-operative monitoring solutions. Further, the company provides hearing assessment, screening, and instrument fitting solutions; jaundice management products; brain injury products; and eye imaging systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging. Additionally, it offers essential products used in the everyday operation of neonatal intensive care unit (NICU); balance assessment systems to evaluate patients with balance disorders; and NICVIEW, a live streaming video for families with babies in the NICU. The company also provides computer-based audiological, otoneurologic, and vestibular instrumentation for hearing and balance care professionals. It serves university medical centers, public and private hospitals, physician offices, clinics, research laboratories, and others. The company was formerly known as ALGOTEK Instruments, Inc. and changed its name to Natus Medical Incorporated in September 1988. Natus Medical Incorporated was incorporated in 1987 and is headquartered in Middleton, Wisconsin.
TransMedics Group logo

TransMedics Group

NASDAQ:TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.